Ideaya Biosciences Price Pattern Analysis
| IDYA Stock | USD 28.32 0.08 0.28% |
Momentum
OversoldOverbought
43 · Soft
EPS Estimate Next Quarter -0.99 | EPS Estimate Current Year -4.31 | EPS Estimate Next Year -3.81 | Wall Street Target Price 52.69 | EPS Estimate Current Quarter -0.98 |
How headlines align with Ideaya Biosciences's price movement reveals the strength of sentiment-driven trading. The view compares Ideaya Biosciences' attention signals with peer activity. Ideaya Biosciences' options flow and short interest serve as direct sentiment inputs. Derivatives positioning combined with short selling data strengthens the sentiment reading.
Ideaya Biosciences Current Signal Summary
Ideaya Biosciences's momentum reading (RSI at 0) sits in oversold territory, while the expected daily return of -0.17% is negative and hype elasticity is slightly positive. Daily volatility at 2.98% is moderate, suggesting a standard range of near-term outcomes. Moderate headline density (10 events/month) reflects steady media coverage. Implied volatility at 0.85% indicates the options market expects relatively contained movement. Overall, signals for Ideaya Biosciences are mixed — sentiment is positive despite negative momentum and returns, suggesting speculative interest.
Short Interest Detail for Ideaya Biosciences
200 Day MA 30.53 | Short Percent 0.14 | Short Ratio 6.32 | Shares Short Prior Month 9.76 million | 50 Day MA 31.85 |
Ideaya Biosciences Market Sentiment vs Price Pattern
Sentiment signals for Ideaya Biosciences help frame how attention aligns with price direction. Attention signals are mapped against observed price behavior below.
Sentiment-price alignment for Ideaya Biosciences shows how closely attention tracks actual market moves. Attention cycles alongside price movement can reveal persistent behavioral patterns.
Ideaya Biosciences Implied Volatility | 0.85 |
Ideaya Biosciences' implied volatility provides a volatility expectation derived from option pricing. The indicator is a neutral reference for expected variability.
Attention patterns around Ideaya Biosciences reveal how closely headline activity correlates with price direction. Volatility framing alongside headline metrics helps separate signal from noise.
Ideaya Biosciences Post-Event Predicted Price | $ 28.38 |
Hype signals complement forecasting, technicals, and analyst estimates rather than replacing them. Connecting attention data with quantitative and fundamental context strengthens conclusions.
Rule 16 Implied Move for Current Options
Implied volatility converted via Rule 16 indicates a daily move near 0.0531% for 2026-07-17 options. The estimate captures expected movement range implied by market pricing.
Experienced market participants anticipate that Ideaya Biosciences' price will even out over time. Periods when Ideaya Biosciences' deviates significantly from its historical mean may warrant further fundamental analysis.
Post-Sentiment Price Density Analysis
The probability distribution for Ideaya Biosciences shows the range of outcomes the prediction model assigns to future price. The spread of Ideaya Biosciences' distribution is a direct measure of the uncertainty inherent in any forward-looking price model.
Next price density |
| Expected price to next headline |
Estimated Post-Sentiment Price Volatility
Historical news analysis for Ideaya Biosciences provides statistically derived price boundaries for the session following a headline. Ideaya Biosciences' post-sentiment downside and upside margins for the prediction period are 25.40 and 31.36, respectively. This approach captures the empirical distribution of Ideaya Biosciences' short-term price reactions.
Current Value
This after-hype projection for Ideaya Biosciences uses a 3 months horizon to examine how price may behave after short-term sentiment effects dissipate. The objective is to separate event-driven enthusiasm from a more stable price path once the market absorbs the catalyst.
Price Outlook Analysis
Big price swings in a Company such as Ideaya Biosciences are not always tied to earnings or company news. This often happens because big investors are trading Ideaya Biosciences back and forth among themselves. When sentiment drives Ideaya Biosciences above fundamental support, the resulting premium may compress once momentum dissipates. When the sentiment around Ideaya Biosciences fades, the price tends to fall back to levels backed by real results.
| Expected Return | Period Volatility | Sentiment Sensitivity | Peer Sensitivity | News Density | Peer Density | Next Expected Sentiment |
0.17 | 2.98 | 0.06 | 0.22 | 10 Events | 8 Events | In 10 days |
| Latest Traded Price | Expected Post-Event Price | Potential Return on Next Event | Post-Sentiment Volatility | |
28.32 | 28.38 | 0.21 |
|
Market Sentiment Timeline
Ideaya Biosciences is currently traded for 28.32. Ideaya Biosciences has a historical sentiment sensitivity of 0.06. Peers average a sentiment sensitivity of 0.22. is forecasted to increase in value after the next headline, with the post-event price near 28.38 or above. The average volatility of media hype impact on IDYA the price is over 100%. The price jump on the next news is projected to be 0.21%, whereas the daily expected return is currently at -0.17%. The volatility of peer sentiment impact on Ideaya Biosciences is about 231.91%, with the expected peer-implied price after the next announcement near 28.54. IDYA reported previous year's revenue of $218.71 million. Net Loss for the year was -$113.7 million with loss before overhead, payroll, taxes, and interest of -$114.27 million. Given a 90-day horizon, the next forecasted press release will be in 10 days. The Ideaya Biosciences Basic Forecasting Models framework offers a quantitative cross-check for Ideaya Biosciences' projections.For information on how to trade Ideaya Stock refer to our How to Invest in Ideaya Biosciences guide.Related Market Sentiment Analysis
Monitoring how Ideaya Biosciences' competitors respond to market-moving news provides a leading indicator for Ideaya Biosciences. Tracking peer market sentiment helps contextualize Ideaya Biosciences's likely short-term price behavior based on sector news flow.
| SentimentElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SRRK | Scholar Rock Holding | -1.01 | 10 per month | 2.38 | 0.0004 | 7.13 | -4.28 | 18.67 | |
| MLYS | Mineralys Therapeutics Common | 0.60 | 12 per month | 0.00 | -0.01 | 7.60 | -4.48 | 19.52 | |
| ZLAB | Zai Lab | 0.19 | 10 per month | 2.68 | 0.1 | 6.02 | -4.33 | 15.17 | |
| CDTX | Cidara Therapeutics | 0.34 | 29 per month | 1.30 | 0.13 | 5.93 | -4.54 | 105.72 | |
| BEAM | Beam Therapeutics | 0.36 | 11 per month | 4.02 | 0.06 | 8.81 | -7.00 | 24.09 | |
| ADPT | Adaptive Biotechnologies Corp | 0.33 | 11 per month | 0.00 | -0.07 | 5.78 | -6.72 | 17.95 | |
| FOLD | Amicus Therapeutics | 0.34 | 27 per month | 0.00 | 0.14 | 0.21 | -0.14 | 0.49 | |
| KNSA | Kiniksa Pharmaceuticals | 7.14 | 9 per month | 2.27 | 0.11 | 4.19 | -3.90 | 25.08 | |
| LEGN | Legend Biotech Corp | 3.36 | 9 per month | 2.14 | 0.21 | 9.00 | -3.69 | 25.90 | |
| COGT | Cogent Biosciences | 1.20 | 8 per month | 0.00 | -0.03 | 4.94 | -3.55 | 17.20 |
Ideaya Biosciences Additional Predictive Modules
Ideaya Biosciences predictive analysis applies quantitative techniques to historical price data, aiming to identify conditions that have preceded similar moves in the past. Combining multiple forecasting approaches can reduce model-specific bias and improve reliability.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Sentiment Indicators & Methodology
Sentiment analysis for Ideaya Biosciences evaluates news tone, positioning, and narrative momentum. Certain defensive traits may reduce sensitivity to broader macroeconomic fluctuations. Ideaya Biosciences has a market cap of 2.48 billion, ROE of -14.28%.
Ideaya Biosciences analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Sell-side coverage, where present, supplements the data shown.
Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board